|
| Press Releases |
|
 |
|
| Thursday, June 29, 2023 |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
| Wednesday, September 16, 2020 |
|
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
| Wednesday, May 20, 2020 |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
| Thursday, February 27, 2020 |
|
|
NanoViricides has filed Quarterly Report for period ending December 31, 2019; Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its second quarter of financial year 2020 in a timely manner with the Securities and Exchange Commission. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Driving Digital Change: The 33rd Digital Transformation Summit to Shape India's $1 Trillion Digital Market 
Jan 10, 2025 23:24 HKT/SGT
|
|
|
Galaxy Payroll: Driving Innovation in Human Resources Management
Jan 10, 2025 23:35 JST
|
|
|
Viomi Unveils at CES 2025, Leading Innovation in Water Purification Technology
Jan 10, 2025 22:23 HKT/SGT
|
|
|
Revolutionizing Psychology: Asian Conference on Applied Psychology 2025 Unveils VR Networking and Global Collaboration
Jan 10, 2025 20:00 HKT/SGT
|
|
|
Honda 2025 Motorsports Program Overview
Jan 10, 2025 20:26 JST
|
|
|
TOYOTA GAZOO Racing Exhibiting at Tokyo Auto Salon 2025
Jan 10, 2025 18:38 JST
|
|
|
Mazda Introduce the All-NEW "Mazda6" Battery EV in Europe
Jan 10, 2025 17:27 JST
|
|
|
JCB unveils a new e-book that empowers merchants and acquirers to harness growth drivers in the European region
Jan 10, 2025 12:00 JST
|
|
|
NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field
Jan 10, 2025 11:37 JST
|
|
|
Outlander PHEV Tops Canada's Plug-In Hybrid EV Sales in 2024
Jan 10, 2025 9:25 JST
|
|
|
Where is the next Chinese drug that will make MNCs compete to grab orders?
Jan 9, 2025 21:34 HKT/SGT
|
|
|
CONTIOCEAN OFFICIALLY LISTED ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE
Jan 9, 2025 19:56 HKT/SGT
|
|
|
Over 80,000 International Buyers at HKTDC's First Three Trade Fairs in 2025
Jan 9, 2025 19:06 HKT/SGT
|
|
|
Education & Careers Expo opens next Thursday
Jan 9, 2025 18:12 HKT/SGT
|
|
|
Strengthening Supply Chains for a Sustainable Future
Jan 9, 2025 17:44 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
